medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 4

<< Back Next >>

Medicina & Laboratorio 2021; 25 (4)

Langerhans cell histiocytosis, an underdiagnosed lung condition in smokers: case report and literature review

Cabrera-Rojas DL, Gómez-Correa GA, Varela-Aguirre GJ

Language: Spanish
References: 60
Page: 721-734
PDF size: 299.60 Kb.


ABSTRACT

Langerhans cell histiocytosis (LCH) is a disease that can affect patients of any age, but in adults it is a rare disorder of unknown etiology that occurs predominantly in young smokers, without differences in gender. Although certain peculiarities of the disease can be the same than in the pediatric population, the proportion of cases with pulmonary involvement is much higher in adults. It often evolves through successive flare-ups and its severity ranges from benign to life-threatening. Some patients develop significant functional impairment with psychosocial repercussions, that impact the quality of life and are associated with prolonged disability. The diagnostic key will be determined by the history of smoking, and the presence of nodules, cavitated nodules, and thick and thin-walled cysts on high-resolution chest computed tomography (HRCT). However, the definitive diagnosis requires the identification of Langerhans cell granulomas, which is generally achieved by performing a lung biopsy and its histopathological and immunohistochemical study. Today, we could consider this a rare entity, of which there is no clear pathogenic mechanism, and therefore, does not have yet specific therapeutic strategies. The purpose of this review is centered on the diagnostic and therapeutic approach of Langerhans cell histiocytosis in adults, which allows its recognition in early stages and improve the prognosis in people who suffer from it.


REFERENCES

  1. Tazi A. Adult pulmonary Langerhans' cell histiocytosis.Eur Respir J 2006;27:1272-1285. https://doi.org/10.1183/09031936.06.00024004.

  2. Radzikowska E. Pulmonary Langerhans'cell histiocytosis in adults. Adv Respir Med2017;85:277-289. https://doi.org/10.5603/ARM.a2017.0046.

  3. Lichtenstein L. Histiocytosis X; integration ofeosinophilic granuloma of bone, Letterer-Siwedisease, and Schüller-Christian disease as relatedmanifestations of a single nosologic entity.AMA Arch Pathol 1953;56:84-102.

  4. Lampert F. Langerhans cell histiocytosis. Historicalperspectives. Hematol Oncol Clin NorthAm 1998;12:213-219. https://doi.org/10.1016/s0889-8588(05)70506-2.

  5. Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans'cell histiocytosis. Thorax 2000;55:405-416. https://doi.org/10.1136/thorax.55.5.405.

  6. Torre O, Elia D, Caminati A, Harari S.New insights in lymphangioleiomyomatosisand pulmonary Langerhans cell histiocytosis.Eur Respir Rev 2017;26. https://doi.org/10.1183/16000617.0042-2017.

  7. Aricň M, Girschikofsky M, Généreau T, KlersyC, McClain K, Grois N, et al. Langerhanscell histiocytosis in adults. Report from the InternationalRegistry of the Histiocyte Society.Eur J Cancer 2003;39:2341-2348. https://doi.org/10.1016/s0959-8049(03)00672-5.

  8. Weitzman S, Egeler RM. Langerhans cellhistiocytosis: update for the pediatrician.Curr Opin Pediatr 2008;20:23-29. https://doi.org/10.1097/MOP.0b013e3282f45ba4.

  9. Vassallo R, Harari S, Tazi A. Current understandingand management of pulmonaryLangerhans cell histiocytosis. Thorax2017;72:937-945. https://doi.org/10.1136/thoraxjnl-2017-210125.

  10. Emile JF, Abla O, Fraitag S, Horne A, HarocheJ, Donadieu J, et al. Revised classificationof histiocytoses and neoplasms of themacrophage-dendritic cell lineages. Blood2016;127:2672-2681. https://doi.org/10.1182/blood-2016-01-690636.

  11. Colby TV, Lombard C. Histiocytosis X in thelung. Hum Pathol 1983;14:847-856. https://doi.org/10.1016/s0046-8177(83)80160-9.

  12. Favara BE, Feller AC, Pauli M, Jaffe ES,Weiss LM, Arico M, et al. Contemporary classificationof histiocytic disorders. The WHOCommittee On Histiocytic/Reticulum Cell Proliferations.Reclassification Working Groupof the Histiocyte Society. Med Pediatr Oncol1997;29:157-166. https://doi.org/10.1002/(sici)1096-911x(199709)29:3<157::aidmpo1>3.0.co;2-c.

  13. Delobbe A, Durieu J, Duhamel A, WallaertB. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X).Groupe d'Etude en Pathologie Interstitielle dela Société de Pathologie Thoracique du Nord.Eur Respir J 1996;9:2002-2006. https://doi.org/10.1183/09031936.96.09102002.

  14. Vassallo R, Ryu JH, Schroeder DR, DeckerPA, Limper AH. Clinical outcomes of pulmonaryLangerhans'-cell histiocytosis in adults.N Engl J Med 2002;346:484-490. https://doi.org/10.1056/NEJMoa012087.

  15. Aricň M, Egeler RM. Clinical aspects of Langerhanscell histiocytosis. Hematol OncolClin North Am 1998;12:247-258. https://doi.org/10.1016/s0889-8588(05)70508-6.

  16. de Menthon M, Meignin V, Mahr A, TaziA. Histiocytose ŕ cellules de Langerhans del’adulte. Press Medicale 2017;46:55-69. https://doi.org/10.1016/j.lpm.2016.09.015

  17. Elia D, Torre O, Cassandro R, Caminati A,Harari S. Pulmonary Langerhans cell histiocytosis:a comprehensive analysis of 40 patientsand literature review. Eur J Intern Med2015;26:351-356. https://doi.org/10.1016/j.ejim.2015.04.001.

  18. Juvet SC, Hwang D, Downey GP. Rare lungdiseases III: pulmonary Langerhans' cell histiocytosis.Can Respir J 2010;17:e55-62. https://doi.org/10.1155/2010/216240.

  19. Schönfeld N, Dirks K, Costabel U,Loddenkemper R. A prospective clinical multicentrestudy on adult pulmonary Langerhans'cell histiocytosis. Sarcoidosis Vasc Diffuse LungDis 2012;29:132-138.

  20. Murakami I, Matsushita M, Iwasaki T, KuwamotoS, Kato M, Nagata K, et al. Interleukin-1 loop model for pathogenesis of Langerhanscell histiocytosis. Cell Commun Signal2015;13:13. https://doi.org/10.1186/s12964-015-0092-z.

  21. Haroche J, Cohen-Aubart F, Rollins BJ, DonadieuJ, Charlotte F, Idbaih A, et al. Histiocytoses:emerging neoplasia behind inflammation.Lancet Oncol 2017;18:e113-125. https://doi.org/10.1016/s1470-2045(17)30031-1.

  22. Brown NA, Elenitoba-Johnson KSJ. Clinicalimplications of oncogenic mutations in pulmonaryLangerhans cell histiocytosis. CurrOpin Pulm Med 2018;24:281-286. https://doi.org/10.1097/mcp.0000000000000470.

  23. Roden AC, Yi ES. Pulmonary Langerhanscell histiocytosis: An update from the pathologists'perspective. Arch Pathol Lab Med2016;140:230-240. https://doi.org/10.5858/arpa.2015-0246-RA.

  24. Lorillon G, Tazi A. How I manage pulmonaryLangerhans cell histiocytosis.Eur Respir Rev 2017;26. https://doi.org/10.1183/16000617.0070-2017.

  25. Radzikowska E. Update on pulmonary Langerhanscell histiocytosis. Front Med (Lausanne)2020;7:582581. https://doi.org/10.3389/fmed.2020.582581.

  26. Fartoukh M, Humbert M, Capron F, Maître S,Parent F, Le Gall C, et al. Severe pulmonaryhypertension in histiocytosis X. Am J RespirCrit Care Med 2000;161:216-223. https://doi.org/10.1164/ajrccm.161.1.9807024.

  27. Crausman RS, Jennings CA, Tuder RM, AckersonLM, Irvin CG, King TE, Jr. Pulmonaryhistiocytosis X: pulmonary function and exercisepathophysiology. Am J Respir Crit Care Med1996;153:426-435. https://doi.org/10.1164/ajrccm.153.1.8542154.

  28. Harari S, Brenot F, Barberis M, Simmoneau G.Advanced pulmonary histiocytosis X is associatedwith severe pulmonary hypertension. Chest1997;111:1142-1144. https://doi.org/10.1378/chest.111.4.1142-a.

  29. Knight RK. Haemoptysis in eosinophilic granuloma.Br J Dis Chest 1979;73:181-186.

  30. Travis WD, Borok Z, Roum JH, Zhang J,Feuerstein I, Ferrans VJ, et al. PulmonaryLangerhans cell granulomatosis (histiocytosisX). A clinicopathologic study of 48 cases. AmJ Surg Pathol 1993;17:971-986. https://doi.org/10.1097/00000478-199310000-00002.

  31. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilicgranuloma of lung. Clinical aspectsof primary histiocytosis in the adult. Medicine(Baltimore) 1981;60:385-396.

  32. Watanabe R, Tatsumi K, Hashimoto S, TamakoshiA, Kuriyama T. Clinico-epidemiologicalfeatures of pulmonary histiocytosis X.Intern Med 2001;40:998-1003. https://doi.org/10.2169/internalmedicine.40.998.

  33. Abbott GF, Rosado-de Christenson ML,Franks TJ, Frazier AA, Galvin JR. From the archivesof the AFIP: pulmonary Langerhans cellhistiocytosis. Radiographics 2004;24:821-841.https://doi.org/10.1148/rg.243045005.

  34. Grenier P, Valeyre D, Cluzel P, Brauner MW,Lenoir S, Chastang C. Chronic diffuse interstitiallung disease: diagnostic value of chestradiography and high-resolution CT. Radiology1991;179:123-132. https://doi.org/10.1148/radiology.179.1.2006262.

  35. Wang FF, Liu YS, Zhu WB, Liu YD, Chen Y. PulmonaryLangerhans cell histiocytosis in adults:A case report. World J Clin Cases 2019;7:1892-1898. https://doi.org/10.12998/wjcc.v7.i14.1892.

  36. Wei P, Lu HW, Jiang S, Fan LC, Li HP, Xu JF.Pulmonary langerhans cell histiocytosis: caseseries and literature review. Medicine (Baltimore)2014;93:e141. https://doi.org/10.1097/md.0000000000000141.

  37. Lacronique J, Roth C, Battesti JP, Basset F,Chretien J. Chest radiological features of pulmonaryhistiocytosis X: a report based on 50adult cases. Thorax 1982;37:104-109. https://doi.org/10.1136/thx.37.2.104.

  38. Obert J, Vercellino L, Van Der Gucht A, deMargerie-Mellon C, Bugnet E, Chevret S, etal. (18)F-fluorodeoxyglucose positron emissiontomography-computed tomography in themanagement of adult multisystem Langerhanscell histiocytosis. Eur J Nucl Med Mol Imaging2017;44:598-610. https://doi.org/10.1007/s00259-016-3521-3.

  39. Albano D, Bosio G, Giubbini R, Bertagna F.Role of (18)F-FDG PET/CT in patients affectedby Langerhans cell histiocytosis. Jpn J Radiol2017;35:574-583. https://doi.org/10.1007/s11604-017-0668-1.

  40. Hance AJ, Basset F, Saumon G, Danel C,Valeyre D, Battesti JP, et al. Smoking andinterstitial lung disease. The effect of cigarettesmoking on the incidence of pulmonaryhistiocytosis X and sarcoidosis. Ann NY Acad Sci 1986;465:643-656. https://doi.org/10.1111/j.1749-6632.1986.tb18541.x.

  41. Auerswald U, Barth J, Magnussen H. Valueof CD-1-positive cells in bronchoalveolar lavagefluid for the diagnosis of pulmonary histiocytosisX. Lung 1991;169:305-309. https://doi.org/10.1007/bf02714167.

  42. Casolaro MA, Bernaudin JF, Saltini C, FerransVJ, Crystal RG. Accumulation of Langerhans'cells on the epithelial surface of the lower respiratorytract in normal subjects in associationwith cigarette smoking. Am Rev Respir Dis1988;137:406-411. https://doi.org/10.1164/ajrccm/137.2.406.

  43. Myers JL. Other diffuse lung diseases. In:Churg AM, Myers JL, Tazelaar HD, Wrigth JL,eds. Thurlbeck’s Pathology of the Lung. NewYork: Thieme; 2005. p. 601-673.

  44. Popper HH. Die pulmonale Langerhans-zellhistiozytose.Der Pathologe 2015;36:451-457.https://doi.org/10.1007/s00292-015-0052-9.

  45. Lieberman PH, Jones CR, Steinman RM,Erlandson RA, Smith J, Gee T, et al. Langerhanscell (eosinophilic) granulomatosis. A clinicopathologicstudy encompassing 50 years.Am J Surg Pathol 1996;20:519-552. https://doi.org/10.1097/00000478-199605000-00001.

  46. Smetana K, Jr., Mericka O, Saeland S, HomolkaJ, Brabec J, Gabius HJ. Diagnostic relevanceof Langerin detection in cells from bronchoalveolarlavage of patients with pulmonaryLangerhans cell histiocytosis, sarcoidosis andidiopathic pulmonary fibrosis. Virchows Arch2004;444:171-174. https://doi.org/10.1007/s00428-003-0952-6.

  47. Chaowalit N, Pellikka PA, Decker PA, AubryMC, Krowka MJ, Ryu JH, et al. Echocardiographicand clinical characteristics ofpulmonary hypertension complicating pulmonaryLangerhans cell histiocytosis. MayoClin Proc 2004;79:1269-1275. https://doi.org/10.4065/79.10.1269.

  48. Etienne B, Bertocchi M, Gamondes JP, ThévenetF, Boudard C, Wiesendanger T, et al.Relapsing pulmonary Langerhans cell histiocytosisafter lung transplantation. Am J RespirCrit Care Med 1998;157:288-291. https://doi.org/10.1164/ajrccm.157.1.96-12107.

  49. Dauriat G, Mal H, Thabut G, Mornex JF,Bertocchi M, Tronc F, et al. Lung transplantationfor pulmonary langerhans' cell histiocytosis:a multicenter analysis. Transplantation2006;81:746-750. https://doi.org/10.1097/01.tp.0000200304.64613.af.

  50. Boehler A. Lung transplantation for cysticlung diseases: lymphangioleiomyomatosis,histiocytosis x, and sarcoidosis. Semin RespirCrit Care Med 2001;22:509-516. https://doi.org/10.1055/s-2001-18423.

  51. Vassallo R, Ryu JH, Colby TV, Hartman T, LimperAH. Pulmonary Langerhans'-cell histiocytosis.N Engl J Med 2000;342:1969-1978. https://doi.org/10.1056/nejm200006293422607.

  52. Lorillon G, Meignin V, Tazi A. [Adult pulmonaryLangerhans cell histiocytosis]. PresseMed 2017;46:70-78. https://doi.org/10.1016/j.lpm.2016.09.016.

  53. DeMartino E, Go RS, Vassallo R. Langerhanscell histiocytosis and other histiocytic diseasesof the lung. Clin Chest Med 2016;37:421-430.https://doi.org/10.1016/j.ccm.2016.04.005.

  54. Girschikofsky M, Arico M, Castillo D, Chu A, DoberauerC, Fichter J, et al. Management of adultpatients with Langerhans cell histiocytosis: recommendationsfrom an expert panel on behalf ofEuro-Histio-Net. Orphanet J Rare Dis 2013;8:72.https://doi.org/10.1186/1750-1172-8-72.

  55. Adam Z, Szturz P, Vaníček J, Moulis M,Pour L, Krejčí M, et al. Cladribine (2-chlorodeoxyadenosine)in frontline chemotherapyfor adult Langerhans cell histiocytosis: A single-center study of seven cases. Acta Oncol2013;52:994-1001. https://doi.org/10.3109/0284186x.2012.716164.

  56. Basset F, Corrin B, Spencer H, Lacronique J,Roth C, Soler P, et al. Pulmonary histiocytosisX. Am Rev Respir Dis 1978;118:811-820.https://doi.org/10.1164/arrd.1978.118.5.811.

  57. Lombard CM, Medeiros LJ, Colby TV. Pulmonaryhistiocytosis X and carcinoma. Arch PatholLab Med 1987;111:339-341.

  58. Tomashefski JF, Khiyami A, Kleinerman J.Neoplasms associated with pulmonary eosinophilicgranuloma. Arch Pathol Lab Med1991;115:499-506.

  59. Tazi A, de Margerie C, Naccache JM, Fry S,Dominique S, Jouneau S, et al. The naturalhistory of adult pulmonary Langerhans cellhistiocytosis: a prospective multicentre study.Orphanet J Rare Dis 2015;10:30. https://doi.org/10.1186/s13023-015-0249-2.

  60. Shaw B, Borchers M, Zander D, Gupta N. PulmonaryLangerhans cell histiocytosis. SeminRespir Crit Care Med 2020;41:269-279. https://doi.org/10.1055/s-0039-1700996.




2020     |     www.medigraphic.com